Secukinumab and IL-17A: Cytokine Modulation Evidence

Secukinumab IL-17A receptor interaction: what evidence supports downstream cytokine reduction?

Evidence supporting downstream cytokine reduction includes rapid temporal correlation between IL-17A neutralization and suppression of IL-17-dependent mediators, quantitative reductions in cytokines and inflammatory biomarkers, pathway-specific effects with preserved immune function, cellular changes including neutrophil clearance and tissue normalization, and dose-response relationships, though most studies infer receptor interaction from downstream effects rather than measuring direct binding.

Abstract

Secukinumab, a fully human monoclonal antibody, selectively binds and neutralizes IL-17A, with target engagement demonstrated through accumulation of total IL-17A and decreased free IL-17A levels following treatment. Evidence supporting downstream cytokine reduction includes rapid suppression of the IL-23/IL-17 axis beginning at Week 1, with concurrent reductions in IL-17-dependent mediators including beta-defensin2, CXCL1, and CXCL8. Quantitative reductions include IL-6 decreases up to 38.4%, CRP reductions of 35.3%, and IL-17A declines of 42-68% over 52 weeks, with effects sustained for at least one year. The temporal correlation between IL-17A suppression at Week 4 and clinical/histological responses at Week 12, combined with pathway-specific effects (limited TNF-α modulation despite robust IL-17-dependent mediator reduction), establishes a causal link rather than simple correlation. Cellular evidence includes rapid neutrophil clearance, normalization of keratinocyte function, and histological resolution of tissue pathology.

However, most studies infer receptor interaction from downstream effects rather than measuring direct receptor binding or occupancy. The mechanistic sequence—from IL-17A binding through immediate pathway suppression to cytokine reduction and clinical improvement—is supported by dose-response relationships and preserved immune function (maintained T-cell activation and microbial response capacity). The evidence strongly supports that secukinumab’s IL-17A neutralization directly causes downstream cytokine reduction through selective pathway inhibition, though direct receptor binding studies would strengthen mechanistic understanding.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

• Human Participants with Secukinumab
• Cytokine/Inflammatory Marker Measurement
• Comparative or Longitudinal Design
• Appropriate Patient Population
• Acceptable Study Design
• Human Study Focus
• Secukinumab Inclusion
• Adequate Sample Size

Results

Characteristics of Included Studies

The systematic review identified 10 studies evaluating secukinumab’s mechanism of action and downstream effects on cytokine reduction. Studies varied in design, sample size, duration, and full text availability.

Evidence of IL-17A Receptor Interaction

Studies evaluated secukinumab’s mechanism through multiple approaches, though most inferred receptor interaction from downstream effects rather than measuring direct binding. Secukinumab is described as a fully human monoclonal antibody that selectively inhibits IL-17A and binds to human IL-17A, neutralizing its bioactivity.

The mechanism involves direct neutralization of IL-17A’s biological activity, preventing IL-17A from binding to its receptor and triggering downstream inflammatory cascades. Target engagement was demonstrated through accumulation of total IL-17A after treatment initiation, with secukinumab binding to IL-17A reducing its clearance and decreasing free IL-17A levels. This binding creates antibody-antigen complexes that demonstrate target engagement at the molecular level.

Evidence of IL-17A pathway suppression varied across studies. One trial showed reduced expression of IL17A, IL17F, and IL17C mRNA with histological changes in target plaques. Another demonstrated suppression of the IL-23/IL-17 axis evident at Week 1 and continuing through Week 12, including reductions in upstream cytokine IL-23, drug target IL-17A, and downstream targets like beta-defensin2. Studies documented decreased synovial expression of IL-17A associated with clinical improvement, though several studies did not provide direct binding data or specific receptor interaction details.

Downstream Cytokine and Biomarker Reduction

Studies documented comprehensive reductions in inflammatory mediators following secukinumab treatment, though the specific cytokines measured and measurement approaches varied across investigations.

Temporal Correlation Between IL-17A Inhibition and Cytokine Reduction

The timeline of cytokine reduction following secukinumab administration showed remarkably early and sustained effects across multiple studies.

Supporting Biological Evidence

Beyond cytokine measurements, multiple studies documented cellular, histological, and functional changes supporting the IL-17A receptor-mediated mechanism.

Cellular Changes

Neutrophil dynamics showed consistent patterns. Significant clinical responses were associated with extensive clearance of cutaneous neutrophils parallel to normalization of keratinocyte abnormalities and reduction of IL-17-inducible neutrophil chemoattractants (e.g., CXCL1, CXCL8). Baseline biopsies revealed epidermal accumulation of neutrophils and formation of microabscesses in over 60% of cases, with neutrophils representing the numerically largest fraction of infiltrating cells containing IL-17. Following treatment, neutrophil clearance was evident at Week 2, with decreased synovial sublining macrophages (p=0.028) and neutrophils (p=0.004) associated with clinical improvement in joint counts.

Broader immune cell effects included reductions in lesional CD11c-positive dendritic cells and T cells, though these changes were more delayed compared to neutrophil clearance. Importantly, secukinumab did not affect ex vivo T-cell activation, and the capacity of peripheral blood cells to produce cytokines and chemokines upon stimulation with microbial antigens was not affected, suggesting preserved immune function despite cytokine reduction.

Histological Improvements

Tissue-level changes demonstrated resolution of pathological features. Secukinumab reversed plaque histopathology in the majority of patients and modulated a greater proportion of psoriasis disease transcriptome genes (72.1% vs 48.0%) compared to guselkumab, resulting in more histological responders (72.2% vs 53.3%). Specific improvements included reduced epidermal acanthosis, elongated rete ridges, and cellular infiltrates. Additional histological changes encompassed reduction in epidermal thickness, parakeratosis, acanthosis, and numbers of Ki67-positive proliferating epidermal cells.

Gene Expression Changes

Transcriptomic analyses revealed extensive modulation of the IL-17A pathway. Increased expression of IL17A, IL17F, and IL17C appeared in lesional skin, with secukinumab demonstrating suppression of IL-23, IL-17A, and downstream targets like beta-defensin2. Gene set variation analysis showed q values less than 0.05 for changes in IL-17-dependent pathway scores. Significant reduction in IL-17A and IL-17F mRNA levels occurred by Week 2. In synovial tissue, decreased expression of IL-17A was documented, and downregulation of hBD-2 mRNA in keratinocytes suggested normalization of keratinocyte function.

Biomarker Integration

Beyond cytokine measurements, inflammatory biomarkers showed consistent improvement. Significant reductions in CRP and ESR levels were observed, along with decreased MMP-3 production (p<0.01). The reduction in serum CRP and IL-6 levels indicated decreased systemic inflammation. Notably, high-sensitivity CRP decreased by up to 35.3%, and marked reductions in hBD-2 serum concentrations occurred.

One large pooled analysis specifically addressed the neutrophil-lymphocyte ratio (NLR), a predictive biomarker for cardiovascular disease. The decrease in NLR corresponded with decreased neutrophil counts, suggesting effects on neutrophil recruitment and clearance. Stabilization of NLR within physiological ranges suggested normalization of immune response, indicating that while inflammatory neutrophil activity was reduced, overall immune function was preserved.

Evidence Linking IL-17A Inhibition to Cytokine Reduction

Multiple lines of evidence established causal relationships between secukinumab’s IL-17A inhibition and downstream cytokine reduction rather than simple correlation.

Temporal Correlation

Studies consistently demonstrated tight temporal association between IL-17A inhibition and cytokine changes. Suppression of the IL-23/IL-17 axis occurred at Week 1 and continued through Week 12, with clinical and histological responses at Week 12 associated with suppression at Week 4. Secukinumab reduced hsCRP and NLR within weeks 12 to 16, sustained over 52 weeks. The reduction in serum CRP and IL-6 levels indicated a temporal relationship between IL-17A inhibition and cytokine reduction. Decrease in inflammatory cytokines like IL-6, TNF-α, and hsCRP followed secukinumab treatment, and significant IL-17A level reductions occurred at weeks 13, 26, and 52.

Dose-Response Relationships

Several studies provided dose-response evidence. Clinical and histological responses were associated with IL-17A inhibition in a dose-dependent manner, with normalization of epidermal markers more pronounced in the high-dose cohort. Consistent reduction in IL-17A levels occurred with a fixed dose of secukinumab (300 mg every two weeks). Clinically relevant decreases in DAS28-CRP and significant reductions in serum high sensitivity CRP levels appeared with higher doses (75 mg, 150 mg, and 300 mg) compared to placebo.

Mechanistic Explanations

Authors provided biological mechanisms linking IL-17A to cytokine cascades. IL-17A was identified as a critical node in maintaining psoriasis plaques, with its inhibition leading to the reduction of downstream cytokines. IL-17A drives neutrophilic inflammation linked to cardiovascular disease, promotes atherosclerosis and neutrophil recruitment. The blockade of IL-17A’s effect on keratinocytes reduces neutrophil chemoattractants. Direct neutralization of IL-17A inhibits its biological activity, and IL-17A regulates cytokine expression, with secukinumab blocking this regulation.

Control Group Comparisons

Placebo-controlled designs demonstrated pathway specificity. Secukinumab versus guselkumab comparisons showed specificity to the IL-17A pathway, with no consistent effects observed in placebo groups. Significant improvements appeared in secukinumab groups compared to placebo, and effects were specific to secukinumab treatment groups versus placebo. A significant advantage for secukinumab over placebo in reducing hBD-2 levels was documented.

Cellular and Molecular Evidence

Direct mechanistic evidence emerged from multiple approaches. Significant changes in IL-17-dependent pathway scores were observed, with rapid clearance of neutrophils and reduction in IL-17A and IL-17F mRNA levels. Early reductions in IL-17A target genes correlated with clinical responses. Target engagement was demonstrated by increased total IL-17A levels, indicating IL-17A blockade. Clinical improvement linked to histological changes and decreased IL-17A expression, with hBD-2 identified as a downstream marker of the IL-17 pathway, its reduction attributed to IL-17A blockade.

The reduction in NLR and hsCRP associated with neutrophilic inflammation and atherosclerosis provided cellular evidence. Secukinumab did not affect ex vivo T-cell activation, demonstrating specificity.

Synthesis

The evidence across 10 studies, representing diverse populations and methodological approaches, converges on several key findings regarding secukinumab’s mechanism of downstream cytokine reduction through IL-17A inhibition.

• Rapid and Sustained Pathway Modulation: The temporal data reveals a consistent pattern: IL-17A pathway suppression begins within the first week of treatment and is sustained for at least one year. This early onset with concurrent downstream effects argues against indirect mechanisms and supports direct IL-17A neutralization as the primary driver.
• Pathway Specificity and Selectivity: The selective nature of secukinumab’s effects strengthens the mechanistic link. Limited effects on TNF-α mRNA contrast with robust reductions in IL-17-dependent mediators, demonstrating pathway specificity rather than general immunosuppression.
• Molecular Cascade from Target Engagement to Clinical Effect: The evidence supports a clear mechanistic sequence: secukinumab binds IL-17A, demonstrated by accumulation of total IL-17A and reduction in free IL-17A, which prevents receptor activation.
• Quantitative Effects Across Disease States: While the magnitude of cytokine reduction varied across studies, consistent patterns emerged. IL-6 reductions reached 38.4%, CRP decreased by 35.3%, and IL-17A itself declined by 42-68% over 52 weeks.
• Integration of Mechanistic and Clinical Evidence: The mechanistic studies complement clinical trials by elucidating how downstream cytokine reduction translates to therapeutic benefit.
• Limitations in Direct Receptor Binding Data: A notable gap exists in direct receptor binding or occupancy studies.
• Preserved Immune Function Despite Cytokine Reduction: A critical finding is that substantial cytokine reduction does not compromise protective immunity.

References

• J. Krueger et al., 2019
• P. Mease et al., 2015
• G. Bruin et al., 2019
• K. Reich et al., 2015
• I. McInnes et al., 2013
• M. Genovese et al., 2012
• M. Sande et al., 2018
• J. Krueger et al., 2023
• K. Akhmedov et al., 2025
• J. Merola et al., 2022